pCDCAR1 CD19 h(CTLA4ζ)(CAR-MZ001)
The vector of anti-CD19 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD19. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD19 antibody linked to CTLA4 and CD3ζ signaling domains. And the vector product was designed for the treatment of CD19 positive cancers.
Targeting Cell Type
CD19 positive cancers
Discription of Signaling Cassetes
CTLA4 or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152 (cluster of differentiation 152), is a protein receptor that, functioning as an immune checkpoint, downregulates immune responses. CTLA4 is constitutively expressed in Tregs but only upregulated in conventional T cells after activation. It acts as an "off" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells.
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T cell surface antigen Leu-12; B-lymphocyte surface antigen B4; Chronic Lymphocytic Leukemia; CLL; scFv; CD28; Leukemia; chimeric T cell receptors; chimeric immunoreceptors; chimeric antigen receptors; FMC63
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Anti-CD19 scFv h(CD3ζ) CART, pCDCAR1
||Lenti-CD19 CAR (scFv-41BB-CD3ζ, 104880) Viral Particle
||Anti-CD19 (FMC63) h(41BB-CD3ζ,CD20) Self-destruct CAR, pCDCAR1
||Anti-CD19 (Blinatumomab) h(CD28-CD3ζ, EGFRt) Marked CAR, pCDCAR1
||Anti-CD19 h(41BB-CD3ζ, FKBP/FRB) Conditional CAR, pCDCAR1
||Anti-CD19 (S2) h(CD28-CD3ζ) CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-CD28-CD3ζ, SJ25C1) Viral Particle
||Lenti-CD19 CAR (scFv-b2c-CD3ζ, FMC63) Viral Particle
||Anti-CD19 (Inebilizumab) h(CD28-CD3ζ, Anti-CD47 ()) Armoured CAR, pCDCAR1
||Anti-CD19 h(CD3ζ, RXR/EcR) Conditional CAR, pCDCAR1